FACTORS OF ACCESS TO THE MARKET OF INNOVATIVE SPECIALTIES IN ALGERIA: THE CASE OF HOSPITAL DRUGS

被引：0
|
作者：
Djafri, R. [1 ]
Djemai, S. [1 ]
Aissaoui, A. [2 ]
Laichour, A. [2 ]
Boudis, A. [1 ]
机构：
[1] Fac Pharm, Algiers, Algeria
[2] Sanofi, Algiers, Algeria
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HPR145
引用
收藏
页码：S258 / S259
页数：2
相关论文
共 50 条
  • [21] Equity of access to innovative drugs and sustainability of pharmaceutical expenditure
    Eandi, Mario
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2010, 11 (02) : 53 - 54
  • [22] PHARMACEUTICAL MARKET ACCESS IN EMERGING MARKETS THROUGH INNOVATIVE PATIENT ACCESS SCHEMES
    Leibfried, M. J.
    Arsiwalla, M. Y.
    Richardson, S. K.
    VALUE IN HEALTH, 2014, 17 (07) : A417 - A417
  • [23] IMPLICATIONS OF GLOBAL PRICING POLICIES ON ACCESS TO INNOVATIVE DRUGS: THE CASE OF TRASTUZUMAB IN SEVEN LATIN AMERICAN COUNTRIES
    Pichon-Riviere, Andres
    Garay, Osvaldo Ulises
    Augustovski, Federico
    Vallejos, Carlos
    Huayanay, Leandro
    Bueno, Maria del Pilar Navia
    Rodriguez, Alarico
    de Andrade, Carlos Jose Coelho
    Buendia, Jefferson Antonio
    Drummond, Michael
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2015, 31 (1-2) : 2 - 11
  • [24] COMPLEX INNOVATIVE DESIGN TRIALS: TOO COMPLEX FOR MARKET ACCESS?
    Hartikainen, P.
    Kolotourou, K.
    Doolub, N.
    VALUE IN HEALTH, 2020, 23 : S465 - S465
  • [25] Market access for cancer drugs and the role of health economics
    Jonsson, B.
    Wilking, N.
    ANNALS OF ONCOLOGY, 2007, 18 : 55 - 66
  • [26] OPTIMISING MARKET ACCESS FOR ONCOLOGY DRUGS IN BRAZIL & CHINA
    Dummett, H.
    Shankland, B.
    VALUE IN HEALTH, 2010, 13 (03) : A50 - A50
  • [27] MARKET ACCESS VARIATION FOR LIFESTYLE DISEASE DRUGS IN EUROPE
    Bastian, A. W.
    Gea-Sanchez, S.
    Tangari, M.
    VALUE IN HEALTH, 2011, 14 (07) : A339 - A339
  • [28] From patent to patient: analysing access to innovative cancer drugs
    Sharpe, Eva
    Hoey, Richard
    Yap, Christina
    Workman, Paul
    DRUG DISCOVERY TODAY, 2020, 25 (09) : 1561 - 1568
  • [29] Difficulties and challenges in the management of market access for innovative oncological therapies
    Zaniboni, Alberto
    Ravasio, Roberto
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2016, 3 (03) : 165 - 168
  • [30] ORPHAN DRUGS IN FRANCE: KEY MARKET ACCESS INCENTIVES
    Mennezein, L.
    Avot, D.
    Laigle, V
    VALUE IN HEALTH, 2017, 20 (09) : A565 - A565
12345